Статья

An Experimental Group A <i>Streptococcus</i> Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model

Tania Rivera-HernándezAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, AustraliaDiane G. CarnathanEmory Vaccine Center, Emory University, Atlanta, Georgia, USAScott JonesGreat Ormond Street Institute of Child Health, University College London, London, United KingdomAmanda J. CorkAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, AustraliaMark R. DaviesAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, AustraliaPeter M. MoyleAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, AustraliaIstván TóthAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, AustraliaMichael R. BatzloffInstitute for Glycomics, Griffith University, Gold Coast, QLD, AustraliaJames McCarthyAustralian Infectious Diseases Research Centre, QIMR Berghofer Medical Research Institute, Brisbane, QLD, AustraliaVictor NizetDivision of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California—San Diego, La Jolla, California, USADavid GoldblattGreat Ormond Street Institute of Child Health, University College London, London, United KingdomGuido SilvestriEmory Vaccine Center, Emory University, Atlanta, Georgia, USAMark J. WalkerAustralian Infectious Diseases Research Centre, The University of Queensland, St Lucia, QLD, Australia

2019en

ABI

Аннотация

GAS-related diseases disproportionally affect disadvantaged populations (e.g., indigenous populations), and development of a vaccine has been neglected. A recent strong advocacy campaign driven by the World Health Organization and the International Vaccine Institute has highlighted the urgent need for a GAS vaccine. One significant obstacle in GAS vaccine development is the lack of a widely used animal model to assess vaccine efficacy. Researchers in the field use a wide range of murine models of infection and in vitro assays, sometimes yielding conflicting results. Here we present the nonhuman primate pharyngeal infection model as a tool to assess vaccine-induced protection against colonization and clinical symptoms of pharyngitis and tonsillitis. We have tested the efficacy of an experimental vaccine candidate with promising results. We believe that the utilization of this valuable tool by the GAS vaccine research community could significantly accelerate the realization of a safe and effective GAS vaccine for humans.

Перевод пока недоступен

Идентификаторы

DOI: 10.1128/mbio.00693-19

Цитирования и источники

Цитирований: 2Использованных источников: 0

Показатели — AkademScholar